SBC Medical Group (NASDAQ:SBC) and Q Biomed (OTCMKTS:QBIO) Head-To-Head Contrast

Q Biomed (OTCMKTS:QBIO) and SBC Medical Group (NASDAQ:SBC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Earnings and Valuation

This table compares Q Biomed and SBC Medical Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	$0.05	0.00
SBC Medical Group	$205.42 million	1.87	$46.61 million	$0.41	9.15

SBC Medical Group has higher revenue and earnings than Q Biomed. Q Biomed is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Q Biomed and SBC Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
SBC Medical Group	24.28%	24.17%	18.60%

Institutional and Insider Ownership

60.8% of SBC Medical Group shares are held by institutional investors. 28.2% of Q Biomed shares are held by insiders. Comparatively, 89.5% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Q Biomed has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Q Biomed and SBC Medical Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
SBC Medical Group	1	0	1	0	2.00

SBC Medical Group has a consensus target price of $9.00, indicating a potential upside of 140.00%. Given SBC Medical Group’s stronger consensus rating and higher probable upside, analysts clearly believe SBC Medical Group is more favorable than Q Biomed.

Summary

SBC Medical Group beats Q Biomed on 11 of the 12 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.